글로벌 시신경 장애 치료 시장 – 2029년까지의 산업 동향 및 예측

시장 분석 및 규모

최근 몇 년 동안 시신경 장애 치료 시장은 예측 기간 동안 빠르게 성장할 것으로 예상됩니다. 망막과 시신경은 눈의 중요한 요소 중 하나입니다. 망막은 이미지 를 수집하고, 캡처된 이미지는 분석을 위해 뇌로 전송됩니다. 외상, 다발성 경화증(MS) 및 녹내장은 시신경에 영향을 미칩니다. 세계보건기구(WHO)에 따르면 2019년에 22억 명이 시력 장애 또는 실명의 영향을 받았습니다. 백내장, 교정되지 않은 굴절 이상, 각막 혼탁, 녹내장 및 기타 질환은 시력 장애의 가장 흔한 원인 중 하나입니다.

Data Bridge Market Research는 시신경 장애 치료 시장이 2021년에 19억 2천만 달러 규모였으며 2029년까지 27억 3천만 달러에 도달할 것으로 예상되며 2022년부터 2029년까지의 예측 기간 동안 4.50%의 CAGR을 기록할 것으로 분석했습니다. Data Bridge Market Research 팀이 큐레이팅한 시장 보고서에는 심층적인 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석 및 규제 프레임워크가 포함되어 있습니다.

시장 정의

두 번째 뇌신경인 눈의 시신경은 시각을 위해 감각 정보를 뇌로 전달하는 데 도움이 됩니다. 태아 발달 중에 전뇌의 시신경포가 이 신경으로 발달합니다. 시신경이나 뇌로 가는 경로가 손상되면 시력을 잃을 수 있습니다. 녹내장, 시신경 위축, 시신경염, 시신경두 드루젠은 전 세계적으로 발견되는 일반적인 시신경 질환입니다. 이러한 질환의 대부분은 증상에 따라 치료합니다. 치료는 시력을 향상시키지 못할 수 있지만 질병이 진행됨에 따라 시력 상실을 예방하는 데 도움이 될 수 있습니다.

보고 범위 및 시장 세분화

시신경 장애 치료 시장 동향

운전자

• 눈 질환 의 유병률 증가

안구 질환의 유병률 증가는 시신경 장애 치료 시장의 성장을 촉진할 것으로 추정됩니다. 미국 안과 학회에 따르면, 2019년에 약 732만 명이 원발성 개방각 녹내장(POAG) 진단을 받을 것으로 예상되며, 70~79세(32%), 여성(50%), 히스패닉(50%)에서 가장 높은 비율을 보입니다.

• 의료 인프라에 대한 투자 증가

시신경 장애 치료 시장의 성장률에 영향을 미치는 또 다른 중요한 요인은 인프라를 개선하는 데 도움이 되는 의료비 지출 증가입니다. 또한, 다양한 정부 기관은 자금을 늘려 의료 인프라를 개선하고자 하며, 이는 시장 역학에 더욱 영향을 미칠 것입니다.

• 녹내장 발병률 증가

The surging number of glaucoma and multiple sclerosis (M.S.) cases is anticipated to expand the optic nerve disorders treatment market. Glaucoma is referred to a medical condition which is characterized by a rise in intraocular fluid pressure. The inflammation of the optic nerve causes optic neuritis, while other illnesses are triggered by physical injury to the optic nerve or the development of protein or calcium pockets in the optic nerve.

• Growing number of geriatric population

The surging geriatric population is estimated to enhance the market's expansion during the forecast period of 2022-2029. According to the World Health Organization (WHO), the worldwide geriatric population, which was estimated to be over 524 million in 2010, is expected to increase to nearly 2 billion by 2050. Due to their compromised immune systems, geriatrics are more susceptible to the optic nerve disorders treatment market, further estimated to enhance its growth rate.

• High prevalence of multiple sclerosis (M.S.)

The high prevalence of multiple sclerosis (M.S.) is expected to be a major driver for the optic nerve disorders treatment market’s growth. M.S. is an autoimmune disease in which the immune system assaults healthy bodily components, resulting in eyesight loss or decrease in more than half of the cases. As a result, manufacturers are expanding their production capacity in order to develop immunosuppressive medications that improve patients' quality of life. In September 2019, Roche, a Swiss multinational healthcare company, announced the results of clinical studies for Ocrevus, an immunosuppressive medicine, to better understand its impact in relapsing and progressive M.S.

Opportunities

• Increase in the number of research and development activities       

Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the optic nerve disorders treatment market growth. Along with this, rising drug approvals and launches will further propel the market’s growth rate. 

Moreover, rising investment for the development of advanced technologies and an increase in the number of emerging markets will provide beneficial opportunities for the optic nerve disorders treatment market growth during the forecast period.

Restraints/Challenges

On the other hand, high cost high cost associated with the treatment will obstruct the growth rate of market. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the optic nerve disorders treatment market. Additionally, strict regulatory policies and lack of awareness among people will restrain and further impede the growth rate of the market during the forecast period of 2022-2029.

This optic nerve disorders treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the optic nerve disorders treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

Optic nerve disorders treatment market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

COVID-19 Impact on Optic Nerve Disorders Treatment Market

Over the projected period, the optic nerve disorders treatment market was expected to be constrained by the COVID-19 outbreak. Since its emergence in December 2019, the COVID-19  virus has spread to nearly every country on the planet, prompting the World Health Organization (WHO) to declare it a public health emergency. COVID-19, a new coronavirus, was identified as the causal agent in the pneumonia cases. This virus spread quickly over the world, killing a large number of people. COVID-19 was labelled a global pandemic by the World Health Organization (WHO) in March 2020, and rigorous measures to prevent the disease's spread were recommended. Since then, the pandemic has delayed the expansion of the healthcare sector and disrupted the supply chain. Furthermore, governments in many nations had imposed nationwide lockdowns to halt the spread of COVID-19. Similarly, healthcare organizations in numerous nations throughout the world were having difficulty continuing their supply chain activities. The supply chain slowness hampered the optic nerve disorders treatment market.

Recent Development

• In August 2020, the U.S. Food and Drug Administration (FDA) approved Enspryng (satralizumab-mwge) for treating neuromyelitis optica spectrum disorder (NMOSD) in adults. Enspryng was given fast track designation, which expedites the development and review of drugs that are intended to treat a serious condition and show promise of meeting an unmet medical need. The drug was also designated as an orphan drug, which provides financial incentives to help and stimulate drug development for rare disorders.

Global Optic Nerve Disorders Treatment Market Scope

The optic nerve disorders treatment market is segmented on the basis of indication, drug class, diagnosis, dosage form, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Indication

• Glaucoma
• Optic Neuritis
• Optic Nerve Gliomas
• Optic Nerve Drusen
• Optic Nerve Coloboma
• Optic Atrophy
• Others

Drug Class

• Beta Blockers
• Prostaglandins
• Alpha Adrenergic Agonist
• Carbonic Anhydrase Inhibitors
• Antibiotics
• Corticosteroids
• Others

Diagnosis

• Imaging Tests
  • Magnetic resonance imaging (MRI)
• Ophthalmoscopy
• Eye exams

Dosage form

• Tablets
• Injections
• Solution
• Others

Route of Administration

• Oral
• Topical
• Others

End-Users

• Hospitals
• Specialty Clinics
• Homecare
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Optic Nerve Disorders Treatment Market Regional Analysis/Insights

The optic nerve disorders treatment market is analysed and market size insights and trends are provided by country, indication, drug class, diagnosis, dosage form, route of administration, end-users and distribution channel as referenced above.

The countries covered in the optic nerve disorders treatment market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America dominates the optic nerve disorders treatment market because of the presence of major key players and increasing patient population in this region. Additionally, rising healthcare expenditure will further propel the market’s growth rate in this region.

Asia-Pacific are expected to grow during the forecast period of 2022 to 2029 due to the increasing number of government initiatives in this region. Also, development of healthcare infrastructure and rising population will further propel the market’s growth rate in this region.

보고서의 국가 섹션은 또한 개별 시장 영향 요인과 국내 시장의 현재 및 미래 트렌드에 영향을 미치는 규제 변화를 제공합니다. 다운스트림 및 업스트림 가치 사슬 분석, 기술 트렌드 및 포터의 5가지 힘 분석, 사례 연구와 같은 데이터 포인트는 개별 국가의 시장 시나리오를 예측하는 데 사용되는 몇 가지 포인터입니다. 또한 글로벌 브랜드의 존재 및 가용성과 지역 및 국내 브랜드와의 대규모 또는 희소한 경쟁으로 인해 직면한 과제, 국내 관세 및 무역 경로의 영향은 국가 데이터에 대한 예측 분석을 제공하는 동안 고려됩니다.   

경쟁 환경 및 시신경 장애 치료 시장 점유율 분석

시신경 장애 치료 시장 경쟁 구도는 경쟁자별 세부 정보를 제공합니다. 포함된 세부 정보에는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, 연구 개발 투자, 새로운 시장 이니셔티브, 글로벌 입지, 생산 현장 및 시설, 생산 용량, 회사의 강점과 약점, 제품 출시, 제품 폭과 범위, 응용 분야 우위가 있습니다. 제공된 위의 데이터 포인트는 시신경 장애 치료 시장과 관련된 회사의 초점에만 관련이 있습니다.

시신경 장애 치료 시장에서 활동하는 주요 기업은 다음과 같습니다.

• F. 호프만-라 로슈 유한회사(스위스)
• 마일런 NV(미국)
• Teva Pharmaceutical Industries Ltd. (이스라엘)
• 사노피(프랑스)
• 파이저 주식회사(미국)
• GlaxoSmithKline plc (영국)
• 노바티스 AG(스위스)
• 지두스 카딜라(인도)
• 베링거 인겔하임 인터내셔널 GmbH. (독일)
• Apotex Inc. (캐나다)
• 아스트라제네카(영국)
• 존슨앤존슨(미국)
• Bayer AG(독일)
• Sun Pharmaceutical Industries Ltd. (인도)
• LEO Pharma A/S(덴마크)
• Bausch Health Companies Inc. (캐나다)
• 알러간(아일랜드)
• 엘리 릴리 앤드 컴퍼니(미국)
• Aurobindo Pharma(인도)
• 루팡(인도)

SKU-54112